News Related to Refractory Melanoma

Related coverage linked through entity extraction aliases.

TIL therapy shows durable responses in refractory melanoma as adoption expands

May 13, 2026

Tumour-infiltrating lymphocyte therapy has shown durable responses in refractory melanoma, including a 31.4% objective response rate in phase II data. The 2024 FDA approval of Lifileucel marked a milestone as regulators in other markets continue reviews.

Diakonos Oncology DOC1021 Clears Safety Review, Presents Data at Major Cancer Conferences

Mar 18, 2026

Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.